News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
September, 2025
September 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Al-Ola Abdallah: Utility of Thrombopoietin Receptor Agonists for Prolonged Thrombocytopenia After Chimeric Antigen Receptor T-cell Therapy
Al-Ola Abdallah/LinkedIn
May 1, 2025, 10:25

Al-Ola Abdallah: Utility of Thrombopoietin Receptor Agonists for Prolonged Thrombocytopenia After Chimeric Antigen Receptor T-cell Therapy

Al-Ola Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT at the University of Kansas Medical Center, shared an article by Donald Waddell, et al. on X:

“Utility of Thrombopoietin Receptor Agonists for Prolonged Thrombocytopenia After Chimeric Antigen Receptor T-cell Therapy.

  • TPO-RAs did not increase the rate of thrombocytopenia resolution relative to supportive care.
  • Adverse effects requiring therapy modification related to TPO-RAs occurred in 25% of patients.
  • The financial toxicity associated with TPO-RAs was roughly $87,000.”

Al-Ola Abdallah: Utility of Thrombopoietin Receptor Agonists for Prolonged Thrombocytopenia After Chimeric Antigen Receptor T-cell Therapy

Utility of Thrombopoietin Receptor Agonists for Prolonged Thrombocytopenia After Chimeric Antigen Receptor T-cell Therapy.

Authors: Donald Waddell, Jennifer Collins, Sarvnaz Sadrameli

You can Read the Full Article on Journal of Transplantation and Cellular Therapy.

Al-Ola Abdallah: Utility of Thrombopoietin Receptor Agonists for Prolonged Thrombocytopenia After Chimeric Antigen Receptor T-cell Therapy

More posts featuring Al-Ola A Abdallah.

Al-Ola A Abdallah cancer Donald Waddell fight against cancer Global fight against cancer Jennifer Collins OncoDaily Oncology Plasma Cell disorder program Sarvnaz Sadrameli T-cell therapy Thrombocytopenia Thrombopoietin TPO-RAs transplantation and cellular therapy University of Kansas Medical Center
Special Coverage
Voices
Sep 5, 2025, 11:45
Annalice Gandini: A Case Report on the Successful Use of Dual EGFR Blockade
Voices
Sep 5, 2025, 11:43
Conquering Underfunded and Rare Cancers Through Research - Conquer Cancer, the ASCO Foundation
Science
Sep 5, 2025, 11:34
Harpreet Singh: FDA Grants Accelerated Approval to Zongertinib for HER2-Mutant NSCLC
Voices
Sep 5, 2025, 11:26
Jia (Jenny) Liu: Excited to Share that NECTA PANNA-COTA Trial Reaches 100 Patients Enrolled
Voices
Sep 5, 2025, 11:25
Ivana Cattaneo: Excited to Lead European Government Affairs at BeOne Medicines
Voices
Sep 5, 2025, 11:18
Zodwa Dlamini: Advancing Brain Cancer Care: Precision, AI Innovation, and African Insights
Voices
Sep 5, 2025, 11:17
Narjust Florez: Women in Thoracic Oncology Event at WCLC
Voices
Sep 5, 2025, 11:08
Corinne Faivre-Finn: A Real Privilege to Attend the First Consensus Meeting on Non-Metastatic NSCLC in Barcelona
Voices
Sep 5, 2025, 10:59
Tricia Hernandez: The Leukemia and Lymphoma Society is Now Blood Cancer United
Voices
Sep 5, 2025, 10:59
The Power of Early Intervention: Transforming Outcomes in Gynecological Cancer - Sarah Cannon Research Institute
Voices
Sep 5, 2025, 10:54
Catherine Alix-Panabières: Shaping the Future of Personalized Medicine at Vision Europe 2030
Voices
Sep 5, 2025, 10:49
Humaid Al-Shamsi: The Spirit of Dedicated Care that Makes BCI the Preferred Destination for Cancer Patients